Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Mazieres, J., Novello, S., De Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Wolf, J., Zeaiter, A., Cardona, A., Balas, B., Karagiannis, T., Chlistalla, M., Smoljanovic, V. and Oh, I. (2017). Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC. J. Thorac. Oncol., 12 (11). S. S1897 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Wolf, J., Helland, A., Oh, I-J, Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V and Novello, S. (2022). Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029

de Castro, J., Novello, S., Mazieres, J., Oh, I-J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., de Marinis, F., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H., Chlistalla, M., Smoljanovic, V. and Wolf, J. (2017). CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

This list was generated on Fri Mar 29 08:30:30 2024 CET.